A phase 3 study of ISIS-TTRrx in TTR-related cardiomyopathy patients

Status: Suspended

Phase of Trial: Phase III

Latest Information Update: 26 Aug 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Inotersen (Primary)
Indications Amyloidosis; Cardiomyopathies
Focus Registrational; Therapeutic Use
Acronyms CARDIO-TTR
Sponsors GlaxoSmithKline; GSK

Most Recent Events

07 Apr 2016 According to an Ionis Pharmaceuticals media release, the US FDA has placed a clinical hold on the CARDIO-TTR study while GSK provides answers to questions about the protocol stemming from Ionis' ongoing NEURO-TTR study.
03 Nov 2015 Study design presented at the First European Congress on Hereditary ATTR amyloidosis 2015, according to an Isis Pharmaceuticals media release.
24 Apr 2015 New trial record

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight